Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder
Ane Korff, Xiaojing Yang, Ozan Ozdemir, Ananya Samanta, Yong-Dong Wang, Tushar Patni, Alfonso J. Lav / science - Science Translational Medicine, Volume 18, Issue 846, April 2026.
AI Summary: Researchers report that antisense oligonucleotide therapy reversed neurological deficits in mouse models of HNRNPH2‑related neurodevelopmental disorder. The preclinical results provide a targeted mechanism to correct pathogenic RNA processing, moving a once‑untreatable condition toward a plausible therapeutic path — pending the usual caution about translating mice to humans.
Related Stories
CAR‑T depletes mutant calreticulin cells, offering myelofibrosis hope / 1 month
Personalized genetic therapy yields improvements in children with rare epilepsy / 5 wks
Single‑infusion gene editing dramatically lowers LDL cholesterol in early trial / 2 months
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 3 months
New research links adult depression to stalled hippocampal neurogenesis / 7 days
Ultragenyx gene therapy becomes first FDA‑approved treatment for ultra‑rare disease / 8 days
Mass release of next‑generation tumor organoids accelerates research / 22 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Adolescent Health, Nutrition, Genetics, Medicaid and look for the RSS link.
StackHealth Time Machine